Clinical trials: Control
Full Thickness Thermal Burn
StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns
Autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. Autografting is the usual treatment for full-thickness (FT) burns.
- Trial name
- StrataSOMA (NCT04765202)
- Testing
- AG Tx, SOMA Tx
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Stratatech, a Mallinckrodt Company
Chronic Migraine
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Trial name
- NCT03855137
- Testing
- Atogepant 30 mg, Atogepant 60 mg
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 778 people
- Sponsor
- Allergan
Nasal Airway Obstruction
Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study
The purpose of this study is to compare the Vivaer procedure with radiofrequency (RF) energy to sham procedure for treatment of nasal airway obstruction (NAO).
- Trial name
- VATRAC (NCT04549545)
- Testing
- Vivaer ARC Stylus
- Where
- 12 sites in United States
- Volunteers
- 119 people
- Sponsor
- Aerin Medical
Dup15q Syndrome
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome
This study consists of two parts. Part 1 will evaluate the safety, efficacy, and pharmacodynamics of 52-weeks of basmisanil treatment in children and adolescents (aged 2-14 years) with Dup15q syndrome.
- Trial name
- NCT05307679
- Testing
- Basmisanil
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche
Actinic Keratosis (AK)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.
- Trial name
- NCT01926496
- Testing
- Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5%
- Where
- 46 sites in France, Germany and 1 more
- Volunteers
- 485 people
- Sponsor
- LEO Pharma
Generalized Myasthenia Gravis
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
- Trial name
- ADAPT (NCT03669588)
- Testing
- ARGX-113
- Where
- 66 sites in United States, Belgium and 14 more
- Volunteers
- 167 people
- Sponsor
- argenx
Pain, Postoperative
Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)
The purpose of this study was to evaluate the efficacy and safety of Etoricoxib compared to placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total knee replacement surgery.
- Trial name
- NCT00820027
- Testing
- Etoricoxib 90 mg, Etoricoxib 120 mg, Ibuprofen 600 mg
- Volunteers
- 776 people
- Sponsor
- Organon and Co
HIV-1-infection
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
- Trial name
- CALIBRATE (NCT04143594)
- Testing
- Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir
- Where
- 53 sites in United States, Dominican Republic and 1 more
- Volunteers
- 183 people
- Sponsor
- Gilead Sciences
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects…
- Trial name
- OraGrowtH210 (NCT04614337)
- Testing
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Where
- 43 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Lumos Pharma
Cancer, Spinal Fractures
CAFE Study - Cancer Patient Fracture Evaluation
The primary objective of this study is to evaluate the safety and effectiveness of balloon kyphoplasty treatment for painful, acute, vertebral compression fractures (VCFs) as compared to standard non-surgical therapy in patients…
- Trial name
- CAFE (NCT00211237)
- Testing
- Balloon Kyphoplasty, Non Surgical Management
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 134 people
- Sponsor
- Medtronic Spine LLC
Non-Small-Cell Lung
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
This study was designed to evaluate the role of canakinumab in combination with docetaxel in subjects with advanced non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy.
- Trial name
- CANOPY-2 (NCT03626545)
- Testing
- Canakinumab, Docetaxel
- Where
- 78 sites in United States, Argentina and 24 more
- Volunteers
- 245 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years.
- Trial name
- NCT03446846
- Testing
- MIN-117 5.0 mg, MIN-117 2.5 mg
- Where
- 47 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Minerva Neurosciences
Thyroidectomy
Superficial, Cervical Block in Thyroid Surgery, a Randomized Controlled Trial
The study investigates the impact on post-operative pain of the superficial cervical block with bupivacaine combined with subcutaneous infiltration of the incisional area in thyroid surgery under general anesthesia.
- Trial name
- NCT00472446
- Testing
- bilateral superficial cervical block
- Where
- Switzerland
- Volunteers
- 183 people
- Sponsor
- Cantonal Hospital of St. Gallen
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myelogenous Leukemia
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Trial name
- NCT00317642
- Testing
- clofarabine (IV formulation), cytarabine
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 326 people
- Sponsor
- Genzyme, a Sanofi Company
Cystic Fibrosis
NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients
This Phase IIB proof-of-concept study would examine the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung disease.
- Trial name
- NCT00809094
- Testing
- N-acetylcysteine (NAC)
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Dizziness Chronic, Vertigo, Peripheral
Virtual Environments for Vestibular Rehabilitation
The specific aims of this pilot project are: Aim #1: Determine the extent to which sensory integration strategies differ between 28 individuals with unilateral vestibular hypofunction and 28 age-matched peers.
- Conditions
- Dizziness Chronic, Vertigo, Peripheral, Fall
- Trial name
- NCT04268745
- Testing
- Balance training, Traditional Vestibular Rehabilitation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- New York University
Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
The purpose of the study is to evaluate the efficacy of bedaquiline (BDQ) compared with rifamycin when administered as part of a treatment regimen with clarithromycin (CAM) and ethambutol (EB) in adult participants with…
- Trial name
- NCT04630145
- Testing
- Bedaquiline, Clarithromycin, Ethambutol
- Where
- 55 sites in Japan, South Korea and 1 more
- Volunteers
- 129 people
- Sponsor
- Janssen Pharmaceutical K.K.